These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 21212677

  • 1. Adherence to disease-modifying therapies in spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project.
    Arroyo E, Grau C, Ramo-Tello C, Parra J, Sánchez-Soliño O, GAP Study Group.
    Eur Neurol; 2011; 65(2):59-67. PubMed ID: 21212677
    [Abstract] [Full Text] [Related]

  • 2. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M, COGIMUS Study Group.
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [Abstract] [Full Text] [Related]

  • 3. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
    Nuijten M, Mittendorf T.
    Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242
    [Abstract] [Full Text] [Related]

  • 4. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
    Reynolds MW, Stephen R, Seaman C, Rajagopalan K.
    Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
    [Abstract] [Full Text] [Related]

  • 5. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.
    Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
    [Abstract] [Full Text] [Related]

  • 6. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
    Gobbi C, Zecca C, Linnebank M, Müller S, You X, Meier R, Borter E, Traber M.
    Eur Neurol; 2013 Aug; 70(1-2):35-41. PubMed ID: 23689307
    [Abstract] [Full Text] [Related]

  • 7. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P, Calabrese M, Biasi G, Gallo P.
    J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
    [Abstract] [Full Text] [Related]

  • 8. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study.
    Beer K, Müller M, Hew-Winzeler AM, Bont A, Maire P, You X, Foulds P, Mårlind J, Curtius D.
    BMC Neurol; 2011 Nov 10; 11():144. PubMed ID: 22074056
    [Abstract] [Full Text] [Related]

  • 9. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.
    Halpern R, Agarwal S, Borton L, Oneacre K, Lopez-Bresnahan MV.
    Adv Ther; 2011 Sep 10; 28(9):761-75. PubMed ID: 21870169
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.
    Sánchez-de la Rosa R, Sabater E, Casado MA, Arroyo R.
    J Med Econ; 2012 Sep 10; 15(3):424-33. PubMed ID: 22217249
    [Abstract] [Full Text] [Related]

  • 11. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
    Calabrese M, Bernardi V, Atzori M, Mattisi I, Favaretto A, Rinaldi F, Perini P, Gallo P.
    Mult Scler; 2012 Apr 10; 18(4):418-24. PubMed ID: 21228025
    [Abstract] [Full Text] [Related]

  • 12. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B.
    Mult Scler; 2012 Aug 10; 18(8):1125-34. PubMed ID: 22194217
    [Abstract] [Full Text] [Related]

  • 13. [Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results].
    Arroyo E, Grau C, Ramo C, Parra J, Sánchez-Soliño O, por el grupo espanol del estudio GAP.
    Neurologia; 2010 Sep 10; 25(7):435-42. PubMed ID: 20964990
    [Abstract] [Full Text] [Related]

  • 14. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E, Meyer K.
    Curr Med Res Opin; 2009 Jun 10; 25(6):1445-54. PubMed ID: 19422279
    [Abstract] [Full Text] [Related]

  • 15. Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.
    Miller DM, Weinstock-Guttman B, Bourdette D, You X, Foulds P, Rudick RA.
    Mult Scler; 2011 Jun 10; 17(6):734-42. PubMed ID: 21300736
    [Abstract] [Full Text] [Related]

  • 16. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
    Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
    J Neurol Sci; 2010 May 15; 292(1-2):28-35. PubMed ID: 20236661
    [Abstract] [Full Text] [Related]

  • 17. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis.
    Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Frohman EM, Kieseier BC, GAP Study Group.
    Eur J Neurol; 2011 Jan 15; 18(1):69-77. PubMed ID: 20561039
    [Abstract] [Full Text] [Related]

  • 18. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 15; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
    Minagara A, Murray TJ, PROOF Study Investigators.
    Curr Med Res Opin; 2008 Apr 15; 24(4):1049-55. PubMed ID: 18315940
    [Abstract] [Full Text] [Related]

  • 20. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
    Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.